ClinicalTrials.gg
CompletedNCT01867437Updated Apr 20, 2017

Effects of RM-493 on Energy Expenditure in Obese Individuals

A Phase 1 interventional study of Placebo and RM-493 in Obesity and Morbid Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-20.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2014, 12 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Enrollment
112th of 150
15 · median 39
Started
2013
with 5 others
Phase 1
13 of 213
1 open now
Registered
84th of 213
by date

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 112th largest by enrollment of the 150 interventional ones that give a count, is one of 6 that started in 2013, is one of 13 in phase 1, and was the 84th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 163 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 110 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 84 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

Background:

  • RM-493 is a drug that stimulates parts of the brain that control eating and metabolism. It has helped to reduce body weight and improve insulin sensitivity in lab tests. However, it is not fully known whether RM-493 causes weight loss by just decreasing appetite or by increasing metabolism or both. Researchers want to see how RM-493 affects metabolism and hormones that affect the metabolic rate. They also want to see how RM-493 affects appetite by assessing feelings of hunger and fullness. They will study this drug in people who are obese but are otherwise in good health.

Objectives:

  • To see how RM-493 affects metabolic rate and appetite in obese but otherwise healthy individuals.

Eligibility:

  • Individuals between 18 and 50 years old who are obese (body mass index between 30 and 40 kg/m2) but are otherwise healthy.

Design:

  • The study consists of three phases. The first phase is the screening visit. The second phase is an 8-day inpatient stay. The final phase is a follow-up phone call one week after the end of the second phase.
  • Participants will be divided into two groups. One group will receive the study drug first, followed by a placebo. The other group will receive the placebo followed by the study drug. The study drug and placebo will be given under the skin for 3 days each by a small device (OmniPod) that normally is used to give insulin to people with diabetes.
  • Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. They will also meet with a dietitian. The OmniPod device will be demonstrated before use.
  • Participants will have the following procedures during their 8-day inpatient stay:
  • Daily exercise routine (walking on treadmill) after setting a comfortable pace (miles per hour) during an exercise test
  • Wear physical activity monitors
  • Body composition study to measure amounts of fat and muscle
  • Calorie controlled study diet
  • Study drug/placebo dose through the OmniPod (Days 2 through 4 and 5 through 7)
  • Metabolic rate studies using a cart or the metabolic chamber
  • Daily blood samples
  • Urine collection for 24 hours
  • Questions about weight history and appetite
  • About a week after the inpatient stay, participants will have a followup phone call to ask about any side effects from the study.
Read the detailed description

Obesity is a chronic relapsing health problem and a strong risk factor for type 2 diabetes, hypertension, heart disease and stroke. Life expectancy is shorter in obese individuals who often suffer from costly related co-morbidities such as certain cancers, liver disease, osteoarthritis, sleep apnea and depression. Weight loss improves the co-morbidities. Diet and exercise are effective in the short term, but are rarely effective over a span of years. New therapies are needed especially for patients with obesity. The melanocortin system, and specifically, melanocortin 4 receptor (MC4R) is involved in the regulation of energy homeostasis and body weight. This role is validated in human genetic mutations, and in animal models of obesity, stimulation of MC4R reduces food intake and increases metabolic rate, causing a reduction in body weight.

RM-493 is a potent, selective peptide agonist for the MC4R that suppressed food intake and reduced body weight in preclinical studies. RM-493 has been studied in single dose and multiple ascending dose clinical studies in obese volunteers. This study is a randomized, double-blind, placebo-controlled, multiple-dose, 2-period, crossover study to assess the effects of RM-493 on resting energy expenditure measured in a room calorimeter. Twelve obese but otherwise healthy adult subjects between the ages of 18 and 50 inclusive, will be enrolled and randomized to one of 2 treatment sequences (RM-493 then placebo; or placebo then RM-493) over an 8-day study interval. Components of 24-hour energy expenditure, exercise induced energy expenditure, spontaneous physical activity, respiratory quotient, safety and pharmacokinetic data will be collected.

03

Conditions studied

  • Obesity
  • Morbid Obesity

Browse trials for

Keywords

  • 24 Hour Energy Expenditure
  • Resting Energy Expenditure
  • Obesity
  • Healthy Volunteers
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 163 are open to participants now.

This study's enrollment of 15 is below the median of 62 across 602 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and female subjects aged 18 to 50 years at screening who meet the following inclusion and exclusion criteria will be eligible for enrollment:

  • Able to provide written prior to any study procedures, and be willing and able to comply with study procedures
  • of 30-40 kg/m(2)
  • Subjects who are medically healthy with normal or clinically insignificant screening results (laboratory profiles, medical histories, and physical examination)
  • Female subjects must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of or abstinence must be used/ practiced throughout the study. Female subjects unable to bear children must have this documented in the case report form (CRF) (i.e., tubal ligation, hysterectomy, or [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH).
  • Female subjects must have a negative serum pregnancy test prior to administering the OmniPod in both Period 1 and Period 2 to continue in the study.
  • Males with female partners of must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the follow up phone call after completion of study treatment. Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time.

Exclusion criteria

EXCLUSION CRITERIA:

  • Pregnant or lactating women
  • Any abnormalities on screening laboratories or physical examination as determined by the Investigator
  • Abnormal 12-lead (ECG) except minor deviations deemed to be of no clinical significance by the Investigator
  • or AST > 1.5 times the (ULN) during screening
  • Treated or untreated hypertension or blood pressure 140/90
  • Treated or untreated diabetes diagnosed as fasting plasma glucose 126 or a 6.5%
  • TSH outside of the normal range
  • Active or history of any significant medical condition such as and including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic or hematological disease.
  • Clinical symptoms of or treatment for sleep apnea (severe snoring, excessive daytime somnolence)
  • Any history of cancer, including personal history or close family history (parents or siblings) of melanoma; and/or personal history of multiple atypical nevi, nevoid basal cell carcinoma syndrome, or a personal history of non-melanoma skin cancer.
  • Bariatric surgery
  • History of recent surgery (within 60 days of screening)
  • Current or recent (within last month) infection or viral illness
  • Prescription drug use including topical and inhalers, and non-prescription medicines with sympathomimetic actions (eg decongestants) if not stopped 1 week prior to and throughout the admission.
  • Weight loss or gain of greater than 3% of body weight in last 3 months
  • Inflexible dietary restrictions
  • Actively training athletes (collegiate or professional level)
  • Cigarette smoking (must be completely nonsmoking for at least 2 months)
  • Dependence on caffeine, alcohol or drugs; unable or unwilling to abstain completely from caffeine and related substances for 72 hours prior to study and throughout the study
  • Claustrophobia or other psychiatric conditions that would preclude participation in all aspects of the study
  • Unable or unwilling to wear an insulin pump for the 6 days of treatment during the study (to deliver test drug and placebo)
  • Participation in an clinical study within the 30 days prior to dosing in the present study
  • Any other reason, which in the opinion of the Investigator, would confound proper interpretation of the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    RM-493

    Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days

    Drug: RM-493

  • Placebo comparator
    Placebo

    Double blind placebo will be administered via subcutaneous infusion for 3 days

    Drug: Placebo

Interventions

  • DrugPlacebo

    Sterile solution (vehicle) for subcutaneous infusion

  • DrugRM-493

    Sterile solution (2mg/ml) for subcutaneous infusion

07

What researchers measure

Primary outcomes

  1. Resting energy expenditure measured in a room calorimeter during continuous subcutaneous infusion of RM-493 or placebo in obese healthy subjects

    Time frame: day 4 and day 7

Secondary outcomes

  1. Total energy expenditure measured in a room calorimeter during continuous subcutaneous infusion of RM-493 or placebo in obese healthy subjects

    Time frame: day 4 and day 7

08

Study locations

1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004 Jun;89(6):2522-5. doi: 10.1210/jc.2004-0288. PubMed 15181019 ↗
  • Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev. 2011 Feb;12(2):131-41. doi: 10.1111/j.1467-789X.2009.00712.x. PubMed 20122135 ↗
  • Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am. 2010 Mar;39(1):1-7. doi: 10.1016/j.gtc.2009.12.014. PubMed 20202574 ↗
  • Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ, Zhao X, Ring M, Psota TL, Cone RD, Panaro BL, Gottesdiener KM, Van der Ploeg LH, Reitman ML, Skarulis MC. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab. 2015 Apr;100(4):1639-45. doi: 10.1210/jc.2014-4024. Epub 2015 Feb 12. PubMed 25675384 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Mar 2014, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2013
First posted
Jun 4, 2013
StartActual
May 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Apr 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01867437
Responsible party
Sponsor
First posted
Jun 4, 2013
Start date
May 2013
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Apr 20, 2017

Study contacts

Monica C Skarulis, M.D.
principal investigator · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion